Description: Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Home Page: veratx.com
VERA Technical Analysis
8000 Marina Boulevard
Brisbane,
CA
94005
United States
Phone:
650 770 0077
Officers
| Name | Title |
|---|---|
| Dr. Marshall Fordyce M.D. | Founder, Pres, CEO & Director |
| Mr. Sean P. Grant M.B.A. | Chief Financial Officer |
| Dr. Celia Lin M.D. | Chief Medical Officer |
| Mr. Joseph R. Young M.B.A. | Sr. VP of Fin. & Chief Accounting Officer |
| Mr. Julien E. Capers J.D. | VP & Head of Legal |
| Ms. Kelly Rauber | VP & Head of HR |
| Mr. Tom Doan | Sr. VP of Devel. Operations |
| Ms. Lauren Frenz | Chief Bus. Officer |
| Dr. Joanne Curley Ph.D. | Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3088 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-05-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |